{
    "clinical_study": {
        "@rank": "95745", 
        "acronym": "H\u00b2O", 
        "arm_group": [
            {
                "arm_group_label": "oxybutynin", 
                "arm_group_type": "Experimental", 
                "description": "Oxybutynin was done at 2.5 mg/day from day 1 to day 4, then at 5 mg/day from day 5 to day 7 and at 7.5 mg/day from day 8 to the end of the 6 weeks."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo was done at 2.5 mg/day from day 1 to day 4, then at 5 mg/day from day 5 to day 7 and at 7.5 mg/day from day 8 to the end of the 6 weeks."
            }
        ], 
        "brief_summary": {
            "textblock": "Evaluation of the effectiveness of oxybutynin in hyperhidrosis"
        }, 
        "brief_title": "Treatment of Hyperhidrosis With Oxybutynin", 
        "completion_date": {
            "#text": "February 2014", 
            "@type": "Actual"
        }, 
        "condition": "Hyperhidrosis", 
        "condition_browse": {
            "mesh_term": "Hyperhidrosis"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age greater than 18 years\n\n          -  Patient affiliated to social security or beneficiary of such a regime\n\n          -  Patient able to consent\n\n          -  Patient with hyperhidrosis, generalized or localized (palmar, plantar, axillary) and\n             whose score HDSS (Hyperidrosis Disease Severity Scale) is greater than two.\n\n        Exclusion Criteria:\n\n          -  Age less than 18 years\n\n          -  Patient who can't be followed\n\n          -  Patient participating in another clinical trial\n\n          -  Pregnant\n\n          -  Woman breastfeeding\n\n          -  Hypersensitivity to oxybutynin or any of the excipients\n\n          -  Risk of urinary retention related disorders uretroprostatiques\n\n          -  Intestinal obstruction\n\n          -  Toxic megacolon\n\n          -  Intestinal atony\n\n          -  Severe Ulcerative Colitis\n\n          -  Myasthenia\n\n          -  Closure glaucoma the anterior chamber angle or slightly deep"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "62", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 13, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01855256", 
            "org_study_id": "RB 12.035 H\u00b2O"
        }, 
        "intervention": [
            {
                "arm_group_label": "oxybutynin", 
                "description": "Oxybutynin is started at a dose of 2.5 mg / day and increased gradually until an effective dose without exceed 7.5 mg / day up to 6 weeks.", 
                "intervention_name": "Oxybutynin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Placebo is started at a dose of 2.5 mg / day and increased gradually until an effective dose without exceed 7.5 mg / day up to 6 weeks.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Oxybutynin", 
                "Mandelic Acids"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "hyperhidrosis", 
            "oxybutynin"
        ], 
        "lastchanged_date": "March 31, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Brest", 
                        "country": "France", 
                        "zip": "29609"
                    }, 
                    "name": "Hospital, Brest"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Landerneau", 
                        "country": "France", 
                        "zip": "29800"
                    }, 
                    "name": "CHG Landerneau"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Morlaix", 
                        "country": "France", 
                        "zip": "29600"
                    }, 
                    "name": "CHG de Morlaix"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Quimper", 
                        "country": "France", 
                        "zip": "29000"
                    }, 
                    "name": "Dermatologist'S Office"
                }
            }
        ], 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "2", 
        "official_title": "Treatment of Hyperhidrosis With Oxybutynin: a Randomized Controlled Double Blind Against Placebo", 
        "overall_official": {
            "affiliation": "ADBO", 
            "last_name": "Martine SCHOLLHAMMER, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "France : ANSM - Agence Nationale de S\u00e9cutit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "February 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Two scales are used for this evaluation (Hyperhydrosis Disease Severity Scale and Dermatology Life Quality Index )", 
            "measure": "Evaluation of the effectiveness of oxybutynin  in hyperhidrosis", 
            "safety_issue": "Yes", 
            "time_frame": "6 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01855256"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Number of Participants with Adverse Events will be followed.", 
            "measure": "Safety evaluation of treatment in this indication", 
            "safety_issue": "Yes", 
            "time_frame": "6 weeks"
        }, 
        "source": "University Hospital, Brest", 
        "sponsors": {
            "collaborator": {
                "agency": "Ministry of Health, France", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "University Hospital, Brest", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}